Literature DB >> 27083182

Genes associated with histopathologic features of triple negative breast tumors predict molecular subtypes.

Kristen S Purrington1,2, Daniel W Visscher3, Chen Wang2, Drakoulis Yannoukakos4, Ute Hamann5, Heli Nevanlinna6, Angela Cox7, Graham G Giles8, Jeanette E Eckel-Passow2, Sotiris Lakis9, Vassiliki Kotoula9, George Fountzilas9, Maria Kabisch5, Thomas Rüdiger10, Päivi Heikkilä11, Carl Blomqvist12, Simon S Cross13, Melissa C Southey14, Janet E Olson2, Judy Gilbert3, Sandra Deming-Halverson15, Veli-Matti Kosma16,17, Christine Clarke18, Rodney Scott19, J Louise Jones20, Wei Zheng15, Arto Mannermaa16,17, Diana M Eccles21, Celine M Vachon2, Fergus J Couch22,23.   

Abstract

Distinct subtypes of triple negative (TN) breast cancer have been identified by tumor expression profiling. However, little is known about the relationship between histopathologic features of TN tumors, which reflect aspects of both tumor behavior and tumor microenvironment, and molecular TN subtypes. The histopathologic features of TN tumors were assessed by central review and 593 TN tumors were subjected to whole genome expression profiling using the Illumina Whole Genome DASL array. TN molecular subtypes were defined based on gene expression data associated with histopathologic features of TN tumors. Gene expression analysis yielded signatures for four TN subtypes (basal-like, androgen receptor positive, immune, and stromal) consistent with previous studies. Expression analysis also identified genes significantly associated with the 12 histological features of TN tumors. Development of signatures using these markers of histopathological features resulted in six distinct TN subtype signatures, including an additional basal-like and stromal signature. The additional basal-like subtype was distinguished by elevated expression of cell motility and glucose metabolism genes and reduced expression of immune signaling genes, whereas the additional stromal subtype was distinguished by elevated expression of immunomodulatory pathway genes. Histopathologic features that reflect heterogeneity in tumor architecture, cell structure, and tumor microenvironment are related to TN subtype. Accounting for histopathologic features in the development of gene expression signatures, six major subtypes of TN breast cancer were identified.

Entities:  

Keywords:  Breast cancer; Gene expression; Germline mutation; Pathology; Tumor biology

Mesh:

Year:  2016        PMID: 27083182      PMCID: PMC5400013          DOI: 10.1007/s10549-016-3775-2

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  49 in total

1.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

Authors:  Brian D Lehmann; Joshua A Bauer; Xi Chen; Melinda E Sanders; A Bapsi Chakravarthy; Yu Shyr; Jennifer A Pietenpol
Journal:  J Clin Invest       Date:  2011-07       Impact factor: 14.808

Review 2.  Triple-negative breast cancer.

Authors:  William D Foulkes; Ian E Smith; Jorge S Reis-Filho
Journal:  N Engl J Med       Date:  2010-11-11       Impact factor: 91.245

3.  Age-related lobular involution and risk of breast cancer.

Authors:  Tia R Milanese; Lynn C Hartmann; Thomas A Sellers; Marlene H Frost; Robert A Vierkant; Shaun D Maloney; V Shane Pankratz; Amy C Degnim; Celine M Vachon; Carol A Reynolds; Romayne A Thompson; L Joseph Melton; Ellen L Goode; Daniel W Visscher
Journal:  J Natl Cancer Inst       Date:  2006-11-15       Impact factor: 13.506

Review 4.  Tumor-stromal interactions in breast tumor progression--significance of histological heterogeneity of tumor-stromal fibroblasts.

Authors:  Takahiro Hasebe
Journal:  Expert Opin Ther Targets       Date:  2013-01-08       Impact factor: 6.902

5.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

6.  Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection.

Authors:  Qiang Gao; Shuang-Jian Qiu; Jia Fan; Jian Zhou; Xiao-Ying Wang; Yong-Sheng Xiao; Yang Xu; Yi-Wei Li; Zhao-You Tang
Journal:  J Clin Oncol       Date:  2007-06-20       Impact factor: 44.544

7.  CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer.

Authors:  Y Naito; K Saito; K Shiiba; A Ohuchi; K Saigenji; H Nagura; H Ohtani
Journal:  Cancer Res       Date:  1998-08-15       Impact factor: 12.701

8.  Independent association of lobular involution and mammographic breast density with breast cancer risk.

Authors:  Karthik Ghosh; Celine M Vachon; V Shane Pankratz; Robert A Vierkant; Stephanie S Anderson; Kathleen R Brandt; Daniel W Visscher; Carol Reynolds; Marlene H Frost; Lynn C Hartmann
Journal:  J Natl Cancer Inst       Date:  2010-10-29       Impact factor: 13.506

9.  Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired.

Authors:  Mojgan Ahmadzadeh; Laura A Johnson; Bianca Heemskerk; John R Wunderlich; Mark E Dudley; Donald E White; Steven A Rosenberg
Journal:  Blood       Date:  2009-05-07       Impact factor: 22.113

10.  A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11.

Authors:  Afshan Siddiq; Fergus J Couch; Gary K Chen; Sara Lindström; Diana Eccles; Robert C Millikan; Kyriaki Michailidou; Daniel O Stram; Lars Beckmann; Suhn Kyong Rhie; Christine B Ambrosone; Kristiina Aittomäki; Pilar Amiano; Carmel Apicella; Laura Baglietto; Elisa V Bandera; Matthias W Beckmann; Christine D Berg; Leslie Bernstein; Carl Blomqvist; Hiltrud Brauch; Louise Brinton; Quang M Bui; Julie E Buring; Saundra S Buys; Daniele Campa; Jane E Carpenter; Daniel I Chasman; Jenny Chang-Claude; Constance Chen; Françoise Clavel-Chapelon; Angela Cox; Simon S Cross; Kamila Czene; Sandra L Deming; Robert B Diasio; W Ryan Diver; Alison M Dunning; Lorraine Durcan; Arif B Ekici; Peter A Fasching; Heather Spencer Feigelson; Laura Fejerman; Jonine D Figueroa; Olivia Fletcher; Dieter Flesch-Janys; Mia M Gaudet; Susan M Gerty; Jorge L Rodriguez-Gil; Graham G Giles; Carla H van Gils; Andrew K Godwin; Nikki Graham; Dario Greco; Per Hall; Susan E Hankinson; Arndt Hartmann; Rebecca Hein; Judith Heinz; Robert N Hoover; John L Hopper; Jennifer J Hu; Scott Huntsman; Sue A Ingles; Astrid Irwanto; Claudine Isaacs; Kevin B Jacobs; Esther M John; Christina Justenhoven; Rudolf Kaaks; Laurence N Kolonel; Gerhard A Coetzee; Mark Lathrop; Loic Le Marchand; Adam M Lee; I-Min Lee; Timothy Lesnick; Peter Lichtner; Jianjun Liu; Eiliv Lund; Enes Makalic; Nicholas G Martin; Catriona A McLean; Hanne Meijers-Heijboer; Alfons Meindl; Penelope Miron; Kristine R Monroe; Grant W Montgomery; Bertram Müller-Myhsok; Stefan Nickels; Sarah J Nyante; Curtis Olswold; Kim Overvad; Domenico Palli; Daniel J Park; Julie R Palmer; Harsh Pathak; Julian Peto; Paul Pharoah; Nazneen Rahman; Fernando Rivadeneira; Daniel F Schmidt; Rita K Schmutzler; Susan Slager; Melissa C Southey; Kristen N Stevens; Hans-Peter Sinn; Michael F Press; Eric Ross; Elio Riboli; Paul M Ridker; Fredrick R Schumacher; Gianluca Severi; Isabel Dos Santos Silva; Jennifer Stone; Malin Sund; William J Tapper; Michael J Thun; Ruth C Travis; Clare Turnbull; Andre G Uitterlinden; Quinten Waisfisz; Xianshu Wang; Zhaoming Wang; Joellen Weaver; Rüdiger Schulz-Wendtland; Lynne R Wilkens; David Van Den Berg; Wei Zheng; Regina G Ziegler; Elad Ziv; Heli Nevanlinna; Douglas F Easton; David J Hunter; Brian E Henderson; Stephen J Chanock; Montserrat Garcia-Closas; Peter Kraft; Christopher A Haiman; Celine M Vachon
Journal:  Hum Mol Genet       Date:  2012-09-13       Impact factor: 6.150

View more
  10 in total

1.  Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer.

Authors:  Roberto A Leon-Ferre; Mei-Yin Polley; Heshan Liu; Judith A Gilbert; Victoria Cafourek; David W Hillman; Ahmed Elkhanany; Margaret Akinhanmi; Jenna Lilyquist; Abigail Thomas; Vivian Negron; Judy C Boughey; Minetta C Liu; James N Ingle; Krishna R Kalari; Fergus J Couch; Daniel W Visscher; Matthew P Goetz
Journal:  Breast Cancer Res Treat       Date:  2017-09-14       Impact factor: 4.872

2.  Treg depletion potentiates checkpoint inhibition in claudin-low breast cancer.

Authors:  Nicholas A Taylor; Sarah C Vick; Michael D Iglesia; W June Brickey; Bentley R Midkiff; Karen P McKinnon; Shannon Reisdorf; Carey K Anders; Lisa A Carey; Joel S Parker; Charles M Perou; Benjamin G Vincent; Jonathan S Serody
Journal:  J Clin Invest       Date:  2017-08-21       Impact factor: 14.808

Review 3.  A clinical calculator to predict disease outcomes in women with triple-negative breast cancer.

Authors:  Mei-Yin C Polley; Roberto A Leon-Ferre; Samuel Leung; Angela Cheng; Dongxia Gao; Jason Sinnwell; Heshan Liu; David W Hillman; Abraham Eyman-Casey; Judith A Gilbert; Vivian Negron; Judy C Boughey; Minetta C Liu; James N Ingle; Krishna Kalari; Fergus Couch; Jodi M Carter; Daniel W Visscher; Torsten O Nielsen; Matthew P Goetz
Journal:  Breast Cancer Res Treat       Date:  2021-01-03       Impact factor: 4.872

4.  Selective activity of deguelin identifies therapeutic targets for androgen receptor-positive breast cancer.

Authors:  Andrew J Robles; Shengxin Cai; Robert H Cichewicz; Susan L Mooberry
Journal:  Breast Cancer Res Treat       Date:  2016-06-02       Impact factor: 4.872

5.  Maximiscin Induces DNA Damage, Activates DNA Damage Response Pathways, and Has Selective Cytotoxic Activity against a Subtype of Triple-Negative Breast Cancer.

Authors:  Andrew J Robles; Lin Du; Robert H Cichewicz; Susan L Mooberry
Journal:  J Nat Prod       Date:  2016-06-16       Impact factor: 4.050

Review 6.  Rare Breast Cancer Subtypes.

Authors:  Sarah Jenkins; Megan E Kachur; Kamil Rechache; Justin M Wells; Stanley Lipkowitz
Journal:  Curr Oncol Rep       Date:  2021-03-23       Impact factor: 5.075

7.  BI-RADS 3-5 microcalcifications can preoperatively predict breast cancer HER2 and Luminal a molecular subtype.

Authors:  DongZhi Cen; Li Xu; Ningna Li; Zhiguang Chen; Lu Wang; Shuqin Zhou; Biao Xu; Chun Ling Liu; Zaiyi Liu; Tingting Luo
Journal:  Oncotarget       Date:  2017-02-21

Review 8.  Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway.

Authors:  Daniela Massihnia; Antonio Galvano; Daniele Fanale; Alessandro Perez; Marta Castiglia; Lorena Incorvaia; Angela Listì; Sergio Rizzo; Giuseppe Cicero; Viviana Bazan; Sergio Castorina; Antonio Russo
Journal:  Oncotarget       Date:  2016-09-13

Review 9.  Precision medicine based on tumorigenic signaling pathways for triple-negative breast cancer.

Authors:  Nan Wu; Jinghua Zhang; Jing Zhao; Kun Mu; Jun Zhang; Zhao Jin; Jinpu Yu; Juntian Liu
Journal:  Oncol Lett       Date:  2018-08-10       Impact factor: 2.967

10.  CLCA2 expression is associated with survival among African American women with triple negative breast cancer.

Authors:  Kristen S Purrington; Jimmie Knight; Gregory Dyson; Rouba Ali-Fehmi; Ann G Schwartz; Julie L Boerner; Sudeshna Bandyopadhyay
Journal:  PLoS One       Date:  2020-04-16       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.